In a report released yesterday, Evan Seigerman from BMO Capital reiterated a Buy rating on Bristol Myers (BMY – Research Report), with a price target of $92.00. The company’s shares closed yesterday at $72.77.
Seigerman covers the Healthcare sector, focusing on stocks such as Eli Lilly & Co, Amgen, and Mirati Therapeutics. According to TipRanks, Seigerman has an average return of 6.9% and a 52.90% success rate on recommended stocks.
In addition to BMO Capital, Bristol Myers also received a Buy from Atlantic Equities’s Steve Chesney in a report issued today. However, on the same day, Barclays maintained a Hold rating on Bristol Myers (NYSE: BMY).
See Insiders’ Hot Stocks on TipRanks >>
Based on Bristol Myers’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $11.22 billion and a net profit of $1.61 billion. In comparison, last year the company earned a revenue of $11.62 billion and had a net profit of $1.55 billion
Based on the recent corporate insider activity of 33 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BMY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1933, New York-based Bristol-Myers Squibb Co. is a global pharmaceutical company, which engages in the development, licensing, manufacturing, distribution, and sale of biopharmaceutical products in several therapeutic areas. These include cancer, HIV/AIDS, cardiovascular disease, diabetes, hepatitis, rheumatoid arthritis and psychiatric disorders.
Read More on BMY:
- Pharma Earnings: Q4 Hits and Misses in a Post-COVID-19 World
- Notable companies reporting before tomorrow’s open
- Prothena reports ‘positive’ topline Phase 1 study results for PRX005
- Bristol-Myers announces CHMP opinion recommending approval for Reblozyl
- Bristol-Myers’ Sotyktu recommended for approval in psoriasis by Europe’s CHMP
